Pregnancy and birth outcomes after SARS-CoV-2 vaccination in pregnancy

Theiler, Regan N.; Wick, Myra J.; Mehta, Ramila A.; Weaver, Amy L.; Virk, Abinash; Swift, Melanie D.

doi:10.1016/j.ajogmf.2021.100467

Cited by 158 publications

(275 citation statements)

References 12 publications

Supporting

Mentioning

249

Contrasting

Unclassified

Order By: Relevance

“…Preliminary studies of these data found no serious safety concerns to maternal or fetal health associated with mRNA vaccination but were limited in their assessment of vaccination events during the first and second trimesters due to ongoing pregnancies [9]. These findings from the CDC are notably consistent with the conclusions from other studies supporting the safety of COVID-19 mRNA vaccination during pregnancy [10,11].…”

Section: Introductionsupporting

confidence: 71%

No evidence of fetal defects or anti-syncytin-1 antibody induction following COVID-19 mRNA vaccination

Lu-Culligan

Tabachnikova

Tokuyama

et al. 2021

Preprint

View full text Add to dashboard Cite

The impact of coronavirus disease 2019 (COVID-19) mRNA vaccination on pregnancy and fertility has become a major topic of public interest. We investigated two of the most widely propagated claims to determine 1) whether COVID-19 mRNA vaccination of mice during early pregnancy is associated with an increased incidence of birth defects or growth abnormalities, and 2) whether COVID-19 mRNA-vaccinated human volunteers exhibit elevated levels of antibodies to the human placental protein syncytin-1. Using a mouse model, we found that intramuscular COVID-19 mRNA vaccination during early pregnancy at gestational age E7.5 did not lead to differences in fetal size by crown-rump length or weight at term, nor did we observe any gross birth defects. In contrast, injection of the TLR3 agonist and double-stranded RNA mimic polyinosinic-polycytidylic acid, or poly(I:C), impacted growth in utero leading to reduced fetal size. No overt maternal illness following either vaccination or poly(I:C) exposure was observed. We also found that term fetuses from vaccinated murine pregnancies exhibit high circulating levels of anti-Spike and anti-RBD antibodies to SARS-CoV-2 consistent with maternal antibody status, indicating transplacental transfer. Finally, we did not detect increased levels of circulating anti-syncytin-1 antibodies in a cohort of COVID-19 vaccinated adults compared to unvaccinated adults by ELISA. Our findings contradict popular claims associating COVID-19 mRNA vaccination with infertility and adverse neonatal outcomes.

show abstract

Section: Introductionsupporting

confidence: 71%

No evidence of fetal defects or anti-syncytin-1 antibody induction following COVID-19 mRNA vaccination

Lu-Culligan

Tabachnikova

Tokuyama

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“… Shimabukuro et al (2021) found in an analysis of data from pregnant women in the V-Safe registry from December 14, 2020 to February 28, 2021 that women who received the Pfizer-BioNtech or Moderna vaccines did not experience problems with or loss of pregnancy differently from nonvaccinated women. Theiler et al (2021) found similar results. Nonpeer reviewed research by CDC researchers of data from the voluntary V-Safe CDC reporting system supports that COVID-19 vaccination has not led to spontaneous abortion in women 6 to 19 weeks pregnant ( Zauche et al, 2021 ).…”

Section: Questions About Covid-19 Vaccinessupporting

confidence: 62%

Fall 2021 Update

Schoonover-Shoffner

2022

Journal of Christian Nursing

View full text Add to dashboard Cite

: The COVID-19 pandemic and subsequent development of COVID vaccines have resulted in unique challenges for nurses. Nurses are being asked to make recommendations about vaccinations that have only been available since December 2020 even as vaccine information evolves on an almost daily basis. Standards of professional care and a Christian perspective on nursing to help guide nurses' practice in the current climate are discussed in this article. An overview of information and research findings published up to October 31, 2021 about COVID-19 vaccination is given to assist nurses in answering vaccination questions.

show abstract

“…Three observational studies investigated the infection rate among vaccinated vs. unvaccinated pregnant women [ 12 , 21 , 24 ]. Among pregnant women who received the Pfizer–BioNTech vaccine, 0.1% (3/2,136) suffered Covid-19 infection within 14 days from the vaccination and 0.4% (9/2,136) did so more than 14 days after the vaccination.…”

Section: Resultsmentioning

confidence: 99%

mRNA Covid-19 vaccines in pregnancy: A systematic review

et al. 2022

View full text Add to dashboard Cite

Objective Pregnancy is a known risk factor for severe Coronavirus disease 2019. It is important to develop safe vaccines that elicit strong maternal and fetal antibody responses. Methods Registries (ClinicalTrials.gov, the WHO Clinical Trial Registry, and the European Union Clinical Trial Registry) and databases (MEDLINE, ScienceDirect, Cochrane Library, Proquest, Springer, medRxiv, and bioRxiv) were systematically searched in June 20–22, 2021, for research articles pertaining to Covid-19 and pregnancy. Manual searches of bioRxiv and medRxiv were also conducted. Inclusion criteria were studies that focused on Covid-19 vaccination among pregnant women, while review articles and non-human studies were excluded. Infection rate, maternal antibody response, transplacental antibody transfer, and adverse events were described. Results There were 13 observational studies with a total of 48,039 pregnant women who received mRNA vaccines. Of those, three studies investigated infection rate, six studies investigated maternal antibody response, seven studies investigated antibody transfer, three studies reported local adverse events, and five studies reported systemic adverse events. The available data suggested that the mRNA-based vaccines (Pfizer–BioNTech and Moderna) can prevent future SARS-CoV-2 infection. These vaccines did not show clear harm in pregnancy. The most commonly encountered adverse reactions were pain at the injection site, fatigue, and headache, but these were transient. Antibody responses were rapid after the first vaccine dose. After the booster, antibody responses were stronger and associated with better transplacental antibody transfer. Longer intervals between first vaccination dose and delivery were also associated with higher antibody fetal IgG and a better antibody transfer ratio. Conclusions The SARS-CoV-2 mRNA vaccines are encouraged for pregnancy. These vaccines can be a safe option for pregnant women and their fetuses. Two vaccine doses are recommended for more robust maternal and fetal antibody responses. Longer latency is associated with higher fetal antibody responses. Further research about its long-term effect on pregnancy is needed. Systematic review registration PROSPERO (CRD42021261684).

show abstract

Pregnancy and birth outcomes after SARS-CoV-2 vaccination in pregnancy

Cited by 158 publications

References 12 publications

No evidence of fetal defects or anti-syncytin-1 antibody induction following COVID-19 mRNA vaccination

No evidence of fetal defects or anti-syncytin-1 antibody induction following COVID-19 mRNA vaccination

Fall 2021 Update

mRNA Covid-19 vaccines in pregnancy: A systematic review

Contact Info

Product

Resources

About